Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $712.3 million.

  • Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity rose 2827.94% to $712.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 1910.89%. This contributed to the annual value of $580.6 million for FY2024, which is 1030.38% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Liabilities and Shareholders Equity of $712.3 million as of Q3 2025, which was up 2827.94% from $661.2 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity's 5-year high stood at $712.3 million during Q3 2025, with a 5-year trough of $210.6 million in Q2 2022.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $483.1 million (2023), whereas its average is $449.7 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity tumbled by 2577.24% in 2022 and then surged by 13000.34% in 2023.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity stood at $232.8 million in 2021, then surged by 97.45% to $459.7 million in 2022, then increased by 14.5% to $526.3 million in 2023, then increased by 10.3% to $580.6 million in 2024, then grew by 22.7% to $712.3 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $712.3 million for Q3 2025, versus $661.2 million for Q2 2025 and $599.3 million for Q1 2025.